PFBT
APLS

Parkside Financial Bank & Trust’s Apellis Pharmaceuticals APLS Stock Holding History

Parkside Financial Bank & Trust’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-119
Closed -$4.79K – 2708
2026
Q1 		$4.79K Buy
119
+86
+261% +$1.85K ﹤0.01% 1838
2025
Q4 		$829 Sell
33
-3
-8% -$70 ﹤0.01% 2404
2025
Q3 		$815 Hold
36
– – ﹤0.01% 2370
2025
Q2 		$624 Buy
36
+31
+620% +$574 ﹤0.01% 2424
2025
Q1 		$110 Sell
5
-24
-83% -$663 ﹤0.01% 2714
2024
Q4 		$926 Sell
29
-1
-3% -$30 ﹤0.01% 1757
2024
Q3 		$866 Sell
30
-14
-32% -$518 ﹤0.01% 1734
2024
Q2 		$1.69K Hold
44
– – ﹤0.01% 1577
2024
Q1 		$2.59K Hold
44
– – ﹤0.01% 1470
2023
Q4 		$2.63K Sell
44
-5
-10% -$254 ﹤0.01% 1449
2023
Q3 		$1.86K Buy
+49
New +$2.15K ﹤0.01% 1679

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Parkside Financial Bank & Trust's APLS Position: Q2 2026 in Review

Parkside Financial Bank & Trust sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 119 shares — an estimated $4.79K sold.

Parkside Financial Bank & Trust first reported a position in APLS in Q3 2023 and held it in 11 quarters. The position peaked at $4.79K in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Parkside Financial Bank & Trust reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Parkside Financial Bank & Trust sold 119 Apellis Pharmaceuticals shares in Q2 2026, an estimated $4.79K.
  • Parkside Financial Bank & Trust first reported a position in Apellis Pharmaceuticals in Q3 2023 and held it in 11 quarters.
  • Parkside Financial Bank & Trust's Apellis Pharmaceuticals position peaked at $4.79K in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.